Meeting
2023 ASCO Breakthrough
LCK and resistance to cytotoxic chemotherapy via activating an AXL-PEAK1 signaling axis in cholangiocarcinoma.
Authors
Shohei Takaichi
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN
Shohei Takaichi , Dong-Gi Mun , Mincheng Yu , Jennifer L Tomlinson , Amro M Abdelrahman , Danielle M Carlson , Nathan W Werneburg , Xinyan Wu , Akhilesh Pandey , Gregory J Gores , Rory L Smoot
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Breast Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Hematologic Malignancies,Thoracic Cancers,Other Malignancies or Topics
Sub Track
Targeted Therapies
Citation
JCO Global Oncology 9, 2023 (suppl 1; abstr 27)
DOI
10.1200/GO.2023.9.Supplement_1.27
Abstract #
27
Poster Bd #
C9
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Effect of AXL on cholangiocarcinoma survival and sensitivity to cytotoxic chemotherapy.
First Author: Shohei Takaichi
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Discovery of novel interactions with LCK in cholangiocarcinoma using proximity-dependent biotinylation.
First Author: Jennifer L Tomlinson
Poster
2021 Gastrointestinal Cancers Symposium
Silmitasertib (CX-4945) in combination with gemcitabine and cisplatin as first-line treatment for patients with locally advanced or metastatic cholangiocarcinoma: A phase Ib/II study.
First Author: Mitesh J. Borad
Poster
2021 Gastrointestinal Cancers Symposium
Telotristat ethyl to enhance cytotoxic chemotherapy response in preclinical cholangiocarcinoma models.
First Author: Niranjan Awasthi